Photodermatosis secondary to hydroxyurea.

To cite: Yanamandra U, Sahu KK, Malhotra P, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2014-205974 DESCRIPTION A middle aged Southeast-Asian man, recently diagnosed with chronic myeloid leukaemia (Philadelphia positive on FISH), was started on cytoreductive therapy with hydroxyurea due to high leucocyte count (130 000/mL). The patient had no history of using any other drugs simultaneously or in the recent/remote past. He developed a clearly defined erythematous rash over only those areas of his body exposed to the sun. The rash progressed to confluent epidermal necrosis, denudation with peeling and minimal associated inflammation (figure 1). There was recovery with intact skin (figure 2) after 3 weeks of abstinence of the drug and after using sun blocking measures including sunscreen (SPF-30). He had no history of any idiopathic photodermatoses such as actinic prurigo, hydroa vacciniforme or chronic actinic dermatitis. Features seen in photodermatosis secondary to drugs include: rash predominantly on skin-exposed areas, with clear definition between sun-exposed/ non-exposed areas, and temporal correlation rash from using the implicating drug. In our patient, clues to diagnosis were the presence of the above characteristics, sparing of the upper eye lids and resolution of rash with withdrawal of drug. Also, the presentation suggests photo-toxicity more than